Snapshot from Jun 25, 2026 at 22:38 UTC. For live data and tracking: View Live
Entities / People / Tomas Lorant
Person

Tomas Lorant

Tracked across 1 events · 6 articles · First seen May 27, 2026 · Last active May 27, 2026

Sentiment
60
Attention
4
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the NewsDesk Dashboard
Events (1)
4 60
Business
Hansa Biopharma Idefirix PAES Results
GT Biopharma announced positive topline results from its European 20-HMedIdeS-19 Post Authorization Efficacy Study (PAES) for Imlifidase, a desensitization treatment for highly sensitized kidney transplant patients. The study met its primary objective with 90% one-year…
Impact: As the coordinating investigator for the PAES study, Tomas Lorant confirmed the key role of imlifidase in transforming transplantation care for highly sensitized patients.
May 27, 2026 · 6 articles
NEWSDESK
Track Tomas Lorant live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.